Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02874092 · ClinicalTrials.gov registry record · Phase 4
Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT02874092 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 9 participants.
The verdict
NCT02874092, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is an open label study to assess the improvement in the Disease Activity Score for 28-joint counts (DAS28) with ticagrelor given at 90 mg twice daily in patients with RA who have active disease despite MTX therapy (as defined by the inclusion/exclusion criteria). There will also be a cross sectional analysis of baseline platelet activity in subjects with rheumatoid arthritis and osteoarthritis. Subjects in the OA cohort will not receive any study medication, and will only have one study visit. Patients will receive 90 mg ticagrelor orally bid. The patients will receive drug for 30-days. Methotrexate dose will remain stable throughout the study duration.
Interventions
- DRUG Ticagrelor
- DRUG MTX therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-11-15 |
| Est. Completion | 2019-06-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02874092
The ClinicalTrials.gov registry entry for NCT02874092 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ticagrelor is the first listed.
NCT02874092 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02874092 about?
NCT02874092 is a clinical study titled "Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis". This is an open label study to assess the improvement in the Disease Activity Score for 28-joint counts (DAS28) with ticagrelor given at 90 mg twice daily in patients with RA who have active disease despite MTX therapy (as defined by the inclusion/exclusion criteria). There will also be a cross sect...
What is the current status of trial NCT02874092?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2016-11-15. Estimated completion is 2019-06-19.
What interventions are being tested in trial NCT02874092?
The interventions under investigation include: Ticagrelor (DRUG), MTX therapy (DRUG).
Who is sponsoring clinical trial NCT02874092?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.